JNJ's Tremfya and Carvykti Deliver Promising Results in Clinical Trials
Johnson & Johnson (JNJ) has announced positive findings from clinical trials testing its therapies Tremfya and Carvykti. These treatments are being evaluated for their effectiveness in treating psoriatic arthritis and multiple myeloma.
Tremfya, a fully human monoclonal antibody targeting IL-23 and CD64, achieved key endpoints in the Phase 4 STAR trial. The study focused on biologic-naive adult patients with active psoriatic arthritis presenting axial involvement. At Week 24, patients receiving Tremfya demonstrated significant improvement in composite disease activity scores compared to placebo.
The therapy also reduced axial symptoms and decreased sacroiliac joint inflammation, showing no new safety signals. Axial involvement affects the spine and sacroiliac joints, causing mobility loss and severe pain in a significant percentage of early psoriatic arthritis patients.
Separately, long-term follow-up from Cohort A of the Phase 2 CARTITUDE-2 study revealed that Carvykti delivered five-year progression-free remissions. In this cohort, 50% of relapsed or refractory multiple myeloma patients treated with a single Carvykti infusion remained alive and progression-free at five years without ongoing maintenance therapy.